We provide the latest news
from the world of economics and finance
(RTTNews) - Lyra Therapeutics (LYRA), Monday announced that the phase 3 enlighten trial 1 to evaluate the efficacy and safety of LYR-210 for the treatment of chronic rhinosinusitis or CRS failed to meet the primary endpoint.
CRS is a highly prevalent inflammatory disease of the paranasal sinuses, casuing debilitating symptoms and significant morbidities in people under age 65.
The company stated that the sham-controlled trial failed to show statistically significant improvement compared to the control group in the composite score of the three cardinal symptoms of CRS at 24 weeks.
The biotechnology company further said that data from the 52-week extension phase of the trial is expected in the fourth quarter. Currently, Lyra's stock is moving down 89.91 percent, to $0.40 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.